Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.66), $0.47 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $19.97 million versus the consensus estimate of $34.5 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.